Double Blind, Double Dummy, Multicentre, Randomised, Placebo- Controlled, Crossover Design Clinical Trial of 12 microg (Single Dose and Repeated Doses) Formoterol Fumarate Administered Via pMDI With HFA-134a Propellant or DPI (Aerolizertm Inhaler) in Patients With Partially Reversible COPD.
Phase of Trial: Phase II
Latest Information Update: 15 Dec 2015
At a glance
- Drugs Formoterol (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Sponsors Chiesi Farmaceutici
- 19 Sep 2008 New trial record.